Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
6.19
+0.03 (0.49%)
At close: Jan 21, 2025, 4:00 PM
6.25
+0.06 (0.97%)
After-hours: Jan 21, 2025, 4:30 PM EST
Y-mAbs Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Y-mAbs Therapeutics stock have an average target of 21.1, with a low estimate of 11 and a high estimate of 26. The average target predicts an increase of 240.87% from the current stock price of 6.19.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for YMAB stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 2 | 3 | 3 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 2 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +255.41% | Jan 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 11, 2024 |
| Brookline Capital | Brookline Capital | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +174.64% | Dec 5, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $23 | Buy | Initiates | $23 | +271.57% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +255.41% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
89.99M
from 84.82M
Increased by 6.09%
Revenue Next Year
107.64M
from 89.99M
Increased by 19.62%
EPS This Year
-0.65
from -0.49
EPS Next Year
-0.62
from -0.65
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 95.6M | 124.4M | 136.3M | |||
| Avg | 90.0M | 107.6M | 116.3M | |||
| Low | 83.1M | 89.3M | 89.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 12.7% | 38.2% | 26.6% | |||
| Avg | 6.1% | 19.6% | 8.0% | |||
| Low | -2.0% | -0.8% | -16.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.51 | -0.24 | -0.17 | |||
| Avg | -0.65 | -0.62 | -0.80 | |||
| Low | -0.81 | -0.92 | -1.11 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.